Alliance Pharma Has High Hopes For Recovering Chinese Market in 2023
Executive Summary
Alliance Pharma is hopeful the end to COVID-19 movement restrictions in China will help to boost demand for its key consumer health brands Kelo-cote and Nizoral in 2023.
You may also be interested in...
People On The Move: Appointments At AESGP, Alliance Pharma, FSE, Venture Life
A round-up of the latest appointments in Europe's consumer health industry: AESGP names Haleon's Workman as president; Alliance Pharma shareholders re-elect board; Food Supplements Europe re-elects Stada's Šímová as chair; and Venture Life announces departure of co-Founder and CCO Daly.
Alliance Pharma Enhances US Offering With Perrigo's Scar Treatments
Alliance Pharma has delivered on its commitment to expand its US operations with a deal for Perrigo's ScarAway and Kelo-cote brands. For Perrigo, the divestment brings its acquisition of HRA Pharma a step closer by satisfying competition concerns.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.